C14orf73 Activators
The functional activity of C14orf73, an integral component of the exocyst complex involved in vesicle trafficking, can be enhanced through various biochemical mechanisms facilitated by specific chemical activators. One such pathway involves the direct stimulation of adenylate cyclase, leading to an increase in intracellular cAMP levels, which could enhance the assembly and activity of the exocyst complex. Similarly, the use of cAMP analogs can activate cAMP-dependent pathways, potentially promoting processes that C14orf73 facilitates. The introduction of nonhydrolyzable GTP analogs may activate G-proteins involved in signaling pathways that converge on the exocyst complex, thus enhancing the activity of C14orf73. Additionally, compounds that modulate intracellular calcium levels can activate calcium-dependent proteins that interact with the exocyst complex, influencing C14orf73's role in vesicle tethering and fusion.
Further modulation of C14orf73 activity can be achieved by altering the phosphorylation state of proteins within the exocyst complex. Phosphatase inhibitors can lead to an increased phosphorylation state of these proteins, potentially increasing the activity of C14orf73. In parallel, activators of protein kinase C can modulate vesicle fusion events controlled by the exocyst complex. Disruption of organelle structure, such as that of the Golgi apparatus, may also indirectly enhance the vesicle-tethering function of the exocyst complex and thereby the activity of C14orf73.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
A cAMP analog that activates cAMP-dependent pathways, potentially promoting processes that C14orf73 facilitates as pertains to vesicle trafficking. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC) which can modulate vesicle fusion events controlled by the exocyst complex, including C14orf73. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Increases intracellular calcium, which can activate calcium-dependent proteins that interact with the exocyst complex including C14orf73, influencing vesicle tethering and fusion. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Inhibits protein phosphatases 1 and 2A, leading to increased phosphorylation states of proteins that could enhance the function of the exocyst complex including C14orf73. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A permeable cAMP analog that can activate PKA, potentially leading to phosphorylation events that affect C14orf73's role in the exocyst complex. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
A protein phosphatase inhibitor that can lead to increased phosphorylation of components of the exocyst complex, which may increase the activity of C14orf73. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
A nonhydrolyzable GTP analog that may activate G-proteins involved in signaling pathways that converge on the exocyst complex, potentially enhancing C14orf73 activity. | ||||||
Aluminum Fluoride | 7784-18-1 | sc-291881 sc-291881A | 10 g 50 g | $67.00 $250.00 | ||
Acts as a phosphate analog and activates G-proteins, which could potentiate signaling pathways that involve the exocyst complex and C14orf73. | ||||||
(±)-S-Nitroso-N-acetylpenicillamine | 79032-48-7 | sc-200319B sc-200319 sc-200319A | 10 mg 20 mg 100 mg | $74.00 $114.00 $374.00 | 18 | |
Releases nitric oxide, which can modulate intracellular signaling pathways affecting vesicle transport where C14orf73 plays a role in the exocyst complex. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts the Golgi apparatus and affects vesicle formation, which may indirectly enhance the vesicle-tethering function of the exocyst complex that C14orf73 is a part of. | ||||||